Enovis™ Executives to Present at Prestigious Canaccord Genuity Musculoskeletal Conference

Enovis Corporation

WILMINGTON, DE — Enovis™ Corporation (NYSE: ENOV), a leading player in the healthcare industry, announced this week that top executives from their team will present at the esteemed Canaccord Genuity Musculoskeletal Conference. The conference is scheduled for February 12, 2024, and takes place in San Francisco.

Brady Shirley, President and COO, Ben Berry, CFO, and Louis Vogt, Group President Recon, are slated to make their presentation at 5:30 p.m. ET (2:30 p.m. PT). These high-ranking officials are expected to share insights and updates on the company’s progress and its strategic direction.

Hosted by Canaccord Genuity, an independent full-service financial services firm, the one-day conference explores the current state of various fields within the healthcare sector. It provides a platform for thought leaders to delve into topics like orthopedics, robotic surgery, imaging/enabling technologies, biologics, and regenerative medicine companies.

The event also serves as a prelude to the American Academy of Orthopaedic Surgeons (AAOS) meeting, making it a significant occasion in the healthcare industry calendar.

The presentation by Enovis™ Corporation’s executives is anticipated to provide valuable insights into the company’s operations and strategies. It also offers stakeholders a chance to understand the firm’s perspective on the evolving landscape of the healthcare sector.

A live audio webcast of the presentation, along with a replay of the event, will be available on the company’s website under the Events and Presentations section. This move ensures that those unable to attend the conference can still benefit from the insights shared by the Enovis™ leadership.

The Canaccord Genuity Musculoskeletal Conference continues to be a crucial event for healthcare professionals, providing a platform for in-depth discussions on the latest advancements and trends in the industry. The participation of Enovis™ Corporation’s executives underlines the company’s commitment to staying at the forefront of healthcare innovation and its dedication to continuous learning and growth.

READ:  Prelude Therapeutics Shares Promising Data for CDK9 Inhibitor PRT2527

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.